Status:
RECRUITING
Immunoadsorption Versus Plasma Exchange for Treatment of Guillain-Barré Syndrome (GBS)
Lead Sponsor:
University of Ulm
Collaborating Sponsors:
DiaMed GmbH
Conditions:
GBS
Eligibility:
All Genders
18+ years
Brief Summary
This is an observations study evaluating safety and efficacy of immunoadsorption compared to plasma exchange in Guillain-Barré Syndrome.
Eligibility Criteria
Inclusion
- Diagnosis of Guillain-Barré Syndrome according to the diagnostic criteria proposed by Doorn et al. (Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome, Lancet neurology 2008)
- age 18 years or above
Exclusion
- Clinical or laboratory (C-reactive protein 20 mg/l or above, or evidence of nitrite-positive urinary tract infection) evidence of manifest systemic infection
- Intake of angiotensin converting enzyme inhibitor within1 weeks before first treatment
- Other contraindications against immunoadsorption or plasma exchange
Key Trial Info
Start Date :
April 28 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
May 4 2025
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT04871035
Start Date
April 28 2021
End Date
May 4 2025
Last Update
May 8 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Neurology, University of Ulm
Ulm, Baden-Wurttemberg, Germany, 89081